Literature DB >> 8143099

Prospective multicentric study of the etiology of 1051 bacteremic episodes in 782 cancer patients. CEMIC (French-Belgian Study Club of Infectious Diseases in Cancer).

D Coullioud1, P Van der Auwera, M Viot, C Lasset.   

Abstract

A total of 1051 bacteremic episodes (782 patients) were prospectively recorded in 10 cancer centers (9 French, 1 Belgian), with: patient's age (mean 53, range 1-89 years), underlying cancer, neutropenia (< 1000 neutrophils/microliters; 233), signs and symptoms, type of i.v. line (percutaneous central: 534; peripheral: 228; central implanted: 304), treatment, blood culture system, number of positive blood culture bottles/total obtained, time to growth. Of all episodes, 23.2% occurred within 48 h of admission. The patients were receiving systemic antibiotics at sampling (on AB) in 34.6% of cases. The 1147 pathogens isolated (86 polymicrobial) were: E. coli (10.7%), Klebsiella-Enterobacter-Serratia (6.1%), other enterobacteriaceae (2.2%), Pseudomonas aeruginosa (4.8%), other nonfermenters (4.7%), coagulase-negative staphylococci (CNS, 40.8%), Staphylococcus aureus (9.9%), streptococci (5.4%), enterococci (2.2%), anaerobes (3.4%), yeasts (3.5%), and other bacteria (6.9%). The CDC (Centers for Disease Control) criteria (1988) were used to assess significance: group 1: pathogenic species (616 episodes; 59%); group 2: clinical signs and isolation of a "contaminant" species (47; 4.5%); group 3: as in group 2 with an i.v. line and empiric antibiotic treatment (181 episodes including 176 CNS; 17%); group 4: non-significant (207 episodes including 203 CNS; 20%). Groups 1-3, in which the episodes were considered to be significant (844 episodes; 80%) were compared with non-significant episodes (Fisher). Significant differences (P < or = 0.05) were seen in time to growth (median growth within 24 h vs 48 h), fever (86% vs 54%), chills (40% vs 3%), hypotension (10% vs 2%), septic shock (9% vs 1%), polymicrobial etiology (10% vs 0.5%), and initiation of empiric antibiotic treatment (71% vs 4%). Bacteremic episodes of CDC groups 1, 3 and 4 were further studied in episodes with a single isolate as a doubtful clinical significance (482 episodes) and episodes with > or = 2 bottles positive of probable clinical significance (569 episodes; 54%). In group 1 (218 doubtful, 398 probably significant episodes) significant differences were seen in chills (36% vs 52%), shock (7% vs 13%), polymicrobial (8% vs 17%), initiation of empiric antibiotic treatment (60% vs 72%); in group 3 (87 doubtful, 94 probably significant) in time to growth delay; in group 4 (177 doubtful, 30 probably significant) in proportion with implanted catheter (26% vs 52%), fever (62% vs 10%), and time to growth. This study confirms the predominant role of Gram-positive cocci in bacteremia occurring in cancer patients.

Entities:  

Mesh:

Year:  1993        PMID: 8143099     DOI: 10.1007/bf00326637

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  27 in total

1.  Septicemia in hematologic malignancies: statistical analysis of prognostic factors.

Authors:  A Cortelezzi; F Radaelli; R Mozzana; B M Cesana; L Baldini; E E Polli
Journal:  Haematologica       Date:  1985 Nov-Dec       Impact factor: 9.941

2.  [Incidence of nosocomial infections in an cancer center: clinical and bacteriologic data].

Authors:  D Coullioud; F Combe; J F Latour; F Chauvin; P Bigot
Journal:  Bull Cancer       Date:  1990       Impact factor: 1.276

3.  Bacteroides bacteremia. Experience in a hospital for neoplastic diseases.

Authors:  M F Kagnoff; D Armstrong; A Blevins
Journal:  Cancer       Date:  1972-01       Impact factor: 6.860

4.  A three-year study of positive blood cultures, with emphasis on prognosis.

Authors:  F J Roberts; I W Geere; A Coldman
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

5.  Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group.

Authors: 
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

6.  Streptococcal and enterococcal bacteremia in patients with cancer.

Authors:  A Awada; P van der Auwera; F Meunier; D Daneau; J Klastersky
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

7.  Gram-positive bacteraemia in granulocytopenic cancer patients.

Authors: 
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

8.  The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis.

Authors:  M P Weinstein; J R Murphy; L B Reller; K A Lichtenstein
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb

Review 9.  Gram-positive infections in granulocytopenic patients: an important issue?

Authors:  C Viscoli; P Van der Auwera; F Meunier
Journal:  J Antimicrob Chemother       Date:  1988-04       Impact factor: 5.790

10.  Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia.

Authors:  J C Wade; S C Schimpff; K A Newman; P H Wiernik
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

View more
  11 in total

1.  Validity of earlier positivity of central venous blood cultures in comparison with peripheral blood cultures for diagnosing catheter-related bacteremia in cancer patients.

Authors:  V B Malgrange; M C Escande; S Theobald
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

2.  Patterns and outcome of septicemia in neutropenic children with cancer in a Greek hospital.

Authors:  E Roilides; V Sidi; N Gompakis; M Tsivitanidou; A Katsaveli; D Koliouskas
Journal:  Infection       Date:  1998 May-Jun       Impact factor: 3.553

3.  Mortality related to coagulase-negative staphylococcal bacteremia in febrile neutropenia: A cohort study.

Authors:  Regis G Rosa; Rodrigo P Dos Santos; Luciano Z Goldani
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

Review 4.  Coagulase-negative staphylococci.

Authors:  Karsten Becker; Christine Heilmann; Georg Peters
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

5.  Involvement of oral bacteria and oral immunity as risk factors for chemotherapy-induced fever with neutropenia in patients with hematological cancer.

Authors:  Yuka Sogawa; Makoto Fukui; Shingen Nakamura; Kimiko Sogabe; Ryohei Sumitani; Masami Yoshioka; Masahiro Abe; Daisuke Hinode
Journal:  Int J Hematol       Date:  2020-09-03       Impact factor: 2.490

6.  Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy.

Authors:  Kanako Suzuki; Shinsuke Sasada; Hiromi Nishi; Yuri Kimura; Tomoaki Shintani; Akiko Emi; Norio Masumoto; Takayuki Kadoya; Hiroyuki Kawaguchi; Morihito Okada
Journal:  Breast Cancer       Date:  2022-10-21       Impact factor: 3.307

7.  A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones.

Authors:  M Aoun; P Van der Auwera; I Varthalitis; A M Bourguignon; M Janssen; D Daneau; F Meunier
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

8.  Febrile neutropenia and Fusobacterium bacteremia: clinical experience with 13 cases.

Authors:  P Fanourgiakis; M Vekemans; A Georgala; D Daneau; A Vandermies; P Grenier; M Aoun
Journal:  Support Care Cancer       Date:  2003-03-13       Impact factor: 3.603

9.  Anaerobic bacteremia in a cancer center.

Authors:  L M Noriega; P Van der Auwera; M Phan; D Daneau; F Meunier; J Gerain; M Aoun
Journal:  Support Care Cancer       Date:  1993-09       Impact factor: 3.603

10.  Tolerance of Staphylococcus epidermidis grown from indwelling vascular catheters to antimicrobial agents.

Authors:  N Khardori; M Yassien; K Wilson
Journal:  J Ind Microbiol       Date:  1995-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.